In Europe, 2024 marks the year when exclusivity for a diverse range of drugs encompassing various therapeutic categories is set to expire. This includes established medications like Cabometyx and Zavicefta and breakthrough treatments like Tagrisso.
The article provides a list of 73 such drug patents across diverse therapeutic categories, ranging from antivirals to antineoplastics, reflecting the broad impact of data exclusivity expiration. Whether it’s the widely used Epclusa for hepatitis C or the groundbreaking Venclyxto for chronic lymphocytic leukemia, the expiration signals a paradigm shift in market dynamics across various medical fields by improving access to essential treatments and stimulating innovation.
This is where Elixir comes into play.
Elixir equips generic leaders with a detailed list of expiring drug patents along with regulatory updates and market activities. With this information, companies can strategically plan market entries, navigate regulatory processes efficiently, optimize production, gain a competitive edge, and ensure timely market access for cost-effective alternatives.
See Elixir in action.
73 Drug Patents Exclusivity Expiring in 2024
| Medicine name | Therapeutic area | Data Exclusivity Expiration date | Marketing authorization holder/company name |
| Cabometyx | Carcinoma, Renal Cell; Carcinomas, Hepatocellular | 9-Sep-2024 | Ipsen Pharma |
| Nordimet | Arthritis, Psoriatic; Psoriasis; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid | 18-Aug-2024 | Nordic Group B.V. |
| Bortezomib Hospira | Multiple Myeloma | 22-Jul-2024 | Pfizer Europe MA EEIG |
| Rekovelle | Anovulation | 12-Dec-2024 | Ferring Pharmaceuticals A/S |
| SomaKit TOC | Neuroendocrine Tumors; Radionuclide Imaging | 8-Dec-2024 | Advanced Accelerator Applications |
| Zavicefta | Pneumonia, Bacterial; Soft Tissue Infections; Pneumonia; Urinary Tract Infections; Gram-Negative Bacterial Infections | 23-Jun-2024 | Pfizer Ireland Pharmaceuticals |
| Glyxambi | Diabetes Mellitus, Type 2 | 11-Nov-2024 | Boehringer Ingelheim International GmbH |
| Epclusa | Hepatitis C, Chronic | 6-Jul-2024 | Gilead Sciences Ireland UC |
| Strimvelis | Severe Combined Immunodeficiency | 26-May-2024 | Fondazione Telethon ETS |
| Idelvion | Hemophilia B | 11-May-2024 | CSL Behring GmbH |
| Benepali | Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis | 13-Jan-2024 | Samsung Bioepis NL B.V. |
| Neparvis | Heart Failure | 26-May-2024 | Novartis Europharm Limited |
| Lonsurf | Colorectal Neoplasms | 25-Apr-2024 | Les Laboratoires Servier |
| Ninlaro | Multiple Myeloma | 21-Nov-2024 | Takeda Pharma A/S |
| Amlodipine / Valsartan Mylan | Hypertension | 22-Mar-2024 | Mylan Pharmaceuticals Limited |
| Tagrisso | Carcinoma, Non-Small-Cell Lung | 1-Feb-2024 | AstraZeneca AB |
| Emtricitabine/Tenofovir disoproxil Mylan | HIV Infections | 16-Dec-2024 | Mylan Pharmaceuticals Limited |
| Inhixa | Venous Thromboembolism | 15-Sep-2024 | Techdow Pharma Netherlands B.V. |
| Kovaltry | Hemophilia A | 18-Feb-2024 | Bayer AG |
| Kisplyx | Carcinoma, Renal Cell | 25-Aug-2024 | Eisai GmbH |
| Ivabradine Zentiva | Angina Pectoris; Heart Failure | 11-Nov-2024 | Zentiva, k.s. |
| Tenofovir disoproxil Zentiva | HIV Infections | 15-Sep-2024 | Zentiva k.s. |
| Mysildecard | Hypertension, Pulmonary | 15-Sep-2024 | Viatris Limited |
| Emtricitabine/Tenofovir disoproxil Krka | HIV Infections | 9-Dec-2024 | KRKA, d.d., Novo mesto |
| Ocaliva | Liver Cirrhosis, Biliary | 12-Dec-2024 | ADVANZ PHARMA Limited |
| Sialanar | Sialorrhea | 15-Sep-2024 | Proveca Pharma Limited |
| Zonisamide Mylan | Epilepsy | 31-Mar-2024 | Mylan Pharmaceuticals Limited |
| Ibrance | Breast Neoplasms | 9-Nov-2024 | Pfizer Europe MA EEIG |
| Empliciti | Multiple Myeloma | 11-May-2024 | Bristol-Myers Squibb Pharma EEIG |
| Armisarte (previously Pemetrexed Actavis) | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 18-Jan-2024 | Actavis Group PTC ehf |
| Qtern | Diabetes Mellitus, Type 2; Diabetes Mellitus; Nutritional and Metabolic Diseases; Metabolic Diseases; Glucose Metabolism Disorders | 15-Jul-2024 | Astra Zeneca AB |
| Emtricitabine/Tenofovir disoproxil Zentiva | HIV Infections | 9-Nov-2024 | Zentiva k.s. |
| Cinqaero | Asthma | 15-Aug-2024 | Teva B.V. |
| Galafold | Fabry Disease | 25-May-2024 | Amicus Therapeutics Europe Limited |
| Lopinavir/Ritonavir Mylan | HIV Infections | 14-Jan-2024 | Mylan Pharmaceuticals Limited |
| Neofordex | Multiple Myeloma | 16-Mar-2024 | THERAVIA |
| Atazanavir Mylan | HIV Infections | 22-Aug-2024 | Mylan Pharmaceuticals Limited |
| Eptifibatide Accord | Myocardial Infarction | 11-Jan-2024 | Accord Healthcare S.L.U. |
| Wakix | Narcolepsy | 31-Mar-2024 | Bioprojet Pharma |
| Granpidam | Hypertension, Pulmonary | 14-Nov-2024 | Accord Healthcare S.L.U. |
| Briviact (in Italy: Nubriveo) | Epilepsy | 13-Jan-2024 | UCB Pharma SA |
| Darzalex | Multiple Myeloma | 20-May-2024 | Janssen-Cilag International N.V. |
| Rasagiline Mylan | Parkinson Disease | 4-Apr-2024 | Mylan Pharmaceuticals Limited |
| Taltz | Psoriasis | 25-Apr-2024 | Eli Lilly and Company (Ireland) Limited |
| Vaxelis | Meningitis, Haemophilus; Poliomyelitis; Tetanus; Diphtheria; Whooping Cough; Hepatitis B | 15-Feb-2024 | MCM Vaccine B.V. |
| Odefsey | HIV Infections | 21-Jun-2024 | Gilead Sciences Ireland UC |
| Descovy | HIV Infections | 21-Apr-2024 | Gilead Sciences Ireland UC |
| Venclyxto | Leukemia, Lymphocytic, Chronic, B-Cell | 4-Dec-2024 | AbbVie Deutschland GmbH Co. KG |
| Flixabi | Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Arthritis, Rheumatoid; Crohn Disease; Psoriasis | 26-May-2024 | Samsung Bioepis NL B.V. |
| Coagadex | Factor X Deficiency | 16-Mar-2024 | BPL Bioproducts Laboratory GmbH |
| Oncaspar | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14-Jan-2024 | Les Laboratoires Servier |
| Onivyde pegylated liposomal (previously known as Onivyde) | Pancreatic Neoplasms | 14-Oct-2024 | Les Laboratoires Servier |
| Feraccru | Anemia, Iron-Deficiency | 18-Feb-2024 | Norgine B.V. |
| Zepatier | Hepatitis C, Chronic | 22-Jul-2024 | Merck Sharp & Dohme B.V. |
| Pemetrexed Accord | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 18-Jan-2024 | Accord Healthcare S.L.U. |
| Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) | Influenza, Human | 20-May-2024 | AstraZeneca AB |
| Tenofovir disoproxil Mylan | HIV Infections | 8-Dec-2024 | Mylan Pharmaceuticals Limited |
| Pemetrexed Fresenius Kabi | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 22-Jul-2024 | Fresenius Kabi Deutschland GmbH |
| Uptravi | Hypertension, Pulmonary | 12-May-2024 | Janssen Cilag International NV |
| Ongentys | Parkinson Disease | 24-Jun-2024 | Bial – Portela Cª, S.A. |
| Letifend | 20-Apr-2024 | LETI Pharma, S.L.U. | |
| Sedadex | 12-Aug-2024 | Le Vet Beheer B.V. | |
| Palonosetron Accord | Vomiting; Nausea; Cancer | 26-May-2024 | Accord Healthcare S.L.U. |
| Cepedex | 13-Dec-2024 | CP-Pharma Handelsgesellschaft mbH | |
| Alprolix | Hemophilia B | 12-May-2024 | Swedish Orphan Biovitrum AB (publ) |
| Halagon | 13-Dec-2024 | Emdoka BVBA | |
| Parsabiv | Hyperparathyroidism, Secondary | 11-Nov-2024 | Amgen Europe B.V. |
| Bortezomib Sun | Multiple Myeloma | 22-Jul-2024 | SUN Pharmaceutical Industries (Europe) B.V. |
| Eravac | 22-Sep-2024 | Laboratorios Hipra, S.A. | |
| Sevohale (previously known as Sevocalm) | 21-Jun-2024 | Chanelle Pharmaceuticals Manufacturing Limited | |
| Evalon | 18-Apr-2024 | Laboratorios Hipra, S.A. | |
| EndolucinBeta | Radionuclide Imaging | 6-Jul-2024 | ITM Medical Isotopes GmbH |
| Spectrila | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14-Jan-2024 | Medac Gesellschaft fuer klinische Spezialpraeparate mbH |
With the expiration of patents for 73 drugs in Europe in 2024, patients and healthcare providers will observe increased access to more affordable treatment options and an opportunity to enter previously inaccessible markets. Additionally, the post-exclusivity era will provide a new opportunity for further development and investment in research, leading to the creation of new, innovative formulations and delivery methods.
Now that all the generic drug companies would jump on to the opportunity, the best way forward is to get a headstart with Elixir.
Boost your chances of being the first to know which drugs’ patent exclusivity will expire this year and execute a successful launch of your generic drug manufacturing efforts.
Try Elixir today!
Authored by: Smiksha Sood, Product Development Team
Edited by: Annie Sharma
